Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...